ACAD — ACADIA PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1070494 ·
Last close
$19.58
Market Cap
$3.37B
52W High
$30.96
52W Low
$19.32
ADV30
2,085,241
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 307,959,000 | 279,643,000 | 37,836,000 | 31,500,000 | 1,742,900,000 | 384,985,000 | 436,291,000 |
| Mar 2026 | 268,062,000 | 243,271,000 | -4,616,000 | 3,637,000 | 1,605,230,000 | 282,212,000 | 357,164,000 |
| Dec 2025 | 283,989,000 | 257,764,000 | 17,391,000 | 273,568,000 | 1,564,195,000 | 177,695,000 | 336,805,000 |
| Sep 2025 | 278,633,000 | 256,986,000 | 35,756,000 | 71,779,000 | 1,330,771,000 | 257,996,000 | 413,499,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$123,494,000
Investing CF
$-112,234,000
Financing CF
$52,276,000
CapEx
$-104,735,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$2.20
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,778,249,000
Inventory
$32,372,000
Receivables
$166,330,000
ST Investments
$571,489,000
EBIT TTM
$86,367,000
Pretax Income TTM
$121,368,000
Interest Exp TTM
—
Analysts
20
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,138,643,968
EBITDA
$98,392,000
Free Cash Flow
$68,647,000
Enterprise Value
$3,912,642,560
Total Cash
$956,473,984
Total Debt
$73,854,000
Shares Out
172,305,518
Trailing EPS
$2.23
Book Value
$7.59
ROE
35.7%
ROA
3.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,071,505,000 | 104,811,000 | 391,000,000 | 1,564,195,000 | 336,805,000 | 1,227,390,000 | 109,836,000 |
| Dec 2024 | 957,797,000 | 84,279,000 | 226,451,000 | 1,187,756,000 | 454,963,000 | 732,793,000 | 157,719,000 |
| Dec 2023 | 726,437,000 | -73,379,000 | -61,286,000 | 748,956,000 | 317,201,000 | 431,755,000 | 16,702,000 |
| Dec 2022 | 517,235,000 | -223,596,000 | -215,975,000 | 587,812,000 | 187,399,000 | 400,413,000 | -114,035,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$1,095,250,000
NetIncome TTM
$375,650,000
OpCashFlow TTM
—
Assets (Latest)
$1,605,230,000
Forward EPS
$0.89
Max Pain — expiry 2026-10-16
max pain strike: $22.00 · spot: $19.58 · call oi: 37,732 · put oi: 9,607
Expected Move to 2026-10-16:
±$1.01
(5.16%) —
implied range
$18.57 –
$20.59
· ATM straddle on $20.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PBLS | Parabilis Medicines, Inc. | $3.43B | $28.09 | — |
| IDYA | IDEAYA Biosciences, Inc. | $3.48B | $36.06 | — |
| XENE | Xenon Pharmaceuticals Inc. | $3.50B | $36.16 | — |
| VKTX | Viking Therapeutics, Inc. | $3.23B | $27.73 | — |
| OGN | Organon & Co. | $3.61B | $13.75 | — |
News headlines (Yahoo Finance, 1h cache)
Acadia Pharmaceuticals (ACAD) Secures Patent And Phase 2 Progress, Is It 38% Below Fair Value?
2026-10-06 01:07 · Yahoo
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041
2026-09-28 20:05 · Yahoo
3 Stocks Put Traders Are Targeting Today: AMTX, ACAD, REZI
2026-09-28 15:30 · Yahoo
Acadia Pharmaceuticals (ACAD) Stock Trades At A Discount After A 29% Drop
2026-09-27 07:09 · Yahoo
ACAD Stock Tumbles Today: Analysts Weigh RADIANT Results, Cut Price Targets
2026-09-25 15:22 · Yahoo
Acadia chugs on with Alzheimer’s psychosis programme despite Phase II miss
2026-09-25 15:01 · Yahoo
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
2026-09-25 13:21 · Yahoo
ACADIA Pharmaceuticals (ACAD) Gets ‘Sell’ Rating on Weak Trial Results, Shares Fall 13%
2026-09-25 03:26 · Yahoo
Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026
2026-09-24 22:41 · Yahoo
ACAD Stock Clocks Worst Day In 2 Years After Alzheimer’s Psychosis Drug Misses Main Goal — Citi Cuts Drug’s Success Odds To 20%
2026-09-24 21:51 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.